{"slug":"crystagen","seoKey":"crystagen","displayName":"Crystagen","codes":["EDP","T-36","AC-6"],"synonyms":["Glu-Asp-Pro","H-Glu-Asp-Pro-OH","EDP peptide","T-36 tripeptide","L-glutamyl-L-aspartyl-L-proline","glutamyl-aspartyl-proline (the NLM MeSH supplementary concept heading)","Кристаген / Kristagen (Russian trade name)"],"legalClass":"research_chemical","identifiers":{"pubchemCid":145455337,"inchikey":"CKOFNWCLWRYUHK-XHNCKOQMSA-N","formula":"C14H21N3O8","molecularWeight":359.33,"sequence":"EDP"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and not registered as a substance. Four federal queries returned no match on 2026-09-20: no drug label, no entry in the labelling database, no adverse event report and no record in the substance registration system, which is why there is no UNII. Control queries worked throughout, and the control query in the substance register for a sister peptide of the same research group returned two records, so the absence is a real one. The substance has also never been nominated for the compounding bulks list, whose full text was checked; the dipeptide alanyl-L-glutamine sits there in category 1, so short peptides do appear on that list. A granted US patent exists for the sequence, but a patent is a property right, not an approval.","source":"https://api.fda.gov/drug/label.json?search=openfda.substance_name:%22Crystagen%22"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report and no pharmacopoeial monograph. The register itself could not be queried on 2026-09-20 because the site answered with an authorisation error and an antibot page, so this is a negative finding drawn from the absence of any entry in every other authority database checked and from the absence of any registered clinical development. A granted European patent covers the sequence; that is a right issued by the patent office, not a medicines approval.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=crystagen"},{"market":"DE","status":"not_approved","note":"Neither a national nor an EU marketing authorisation exists, so an injectable preparation is not a marketable medicinal product and may not be imported or dispensed. The substance is also not named in the schedule to the Anti-Doping Act, and no catch-all position of that schedule covers a thymus tripeptide; the full text was checked on 2026-09-20. Sporting rules are unaffected by that. The Russian capsule and sublingual products are food supplements there, not medicines; importing them as food would have to be assessed separately under novel food rules, and no such authorisation is known for the tripeptide.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The product register returned only the JavaScript shell of its search page on 2026-09-20, so the negative finding could not be verified positively. It rests on the absence of any entry elsewhere and on the absence of any clinical development. British research chemical sellers list the substance as research use only, that is, expressly not as a medicine.","source":"https://products.mhra.gov.uk/search/?search=crystagen"},{"market":"AU","status":"not_approved","note":"Not named in the Poisons Standard; the full text of the June 2026 instrument was searched on 2026-09-20 for the trade name, the transliteration and the sequence without a hit. There is no generic peptide position in that instrument, and short peptides are listed by name where they are scheduled, as the control checks for a dipeptide and for two growth hormone secretagogues confirmed. Absence of a listing is not a clearance: an injectable preparation not entered in the therapeutic goods register may not be supplied, and that register itself was not programmatically queryable.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no entry in the drug product database; queries for the trade name and for the transliteration returned empty results on 2026-09-20, while a control query for an authorised product returned its identification number, so the interface was working.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=crystagen"},{"market":"CH","status":"not_approved","note":"No marketing authorisation known. No direct register query was possible on 2026-09-20 because the page addressed returned a not-found error, so this is a negative finding drawn from the absence of an authorisation in every market that could be checked and from the absence of any clinical development programme.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"preclinical","strongestEvidence":"in_vitro","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/145455337"],"lastVerified":"2026-09-20","version":"1.0","published":true,"locale":"en","title":"Crystagen: what the studies show, status and safety","summary":"Crystagen is a synthetic chain of three amino acids from a St Petersburg institute, traded as an immune peptide. Exactly one paper in the medical literature carries its name, and it reports that the substance activates B cells but renews nothing in the ageing spleen. Every immune number quoted for it sits in the inventors' own patent application, including the one occasion on which people received it. It is approved as a medicine nowhere, and it is banned in sport at all times.","updated":"2026-09-20","url":"https://mypep.app/peptides/crystagen"}